🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

When looking for a partner to help you progress your ADC, up-to-date technology is necessary. ThioBridge™ is our proprietary ADC site-specific conjugation technology. Learn more about our ADC services and how we can optimize their therapeutic effect: abzena.com/capabilities/b…

One way to fast-track the progression of biologics to IND is by streamlining cell line development (CLD). Using an integrated approach, CLD can be made shorter, and the path to IND-enabling material can be condensed. Don't believe us? Find out how: abzena.com/capabilities/b…

It's Pride Month! Pride Month is about acceptance, equality and celebrating the work of LGBTQ+ people. As an inclusive employer, we believe LGBTQ+ inclusion should take place all year. That's why we try our best to foster a culture of belonging, built on diversity/inclusion.

The development of ADCs isn't simple. All 4 components of ADCs require optimization, so having a partner well-versed in this space is key. Our vast experience means we know our way around this space, meaning we reliably deliver solutions for you! abzena.com/capabilities/b…

Complications during tech transfer are almost inevitable. In a recent article with Pharmaceutical Technology, our experts outlined the issues you're likely to face during this process and how to best mitigate them. Read it in full here: pharmtech.com/view/communica…

When it comes to the design, development and manufacturing of your ADC, you need sufficient expertise in: ✅Antibodies ✅Targeting Proteins ✅Conjugation Units ✅Polymers ✅Release Linkers ✅Payloads Find out how we can help! 🤝 abzena.com/capabilities/b…

Would you like to be part of a team working towards the improvement of people's health? Working with companies all over the world, Abzena strives to provide the best support to allow these companies to develop better treatment for patients. Learn more: abzena.com/careers/

Today is Independence Day! It marks the day the United States officially became its own nation after the Declaration of Independence was approved by the Continental Congress in 1776. Let us know how you'll be celebrating the occasion! #FourthOfJuly #IndependenceDay

Knowledge/experience means nothing if you don't have the right instruments We have both 😎 ThioBridge™, our linker tech, has the ability to maintain stability of the antibody and a consistent drug-to-antibody ratio, providing a more uniform product. abzena.com/capabilities/b…

Have you ever wondered what it's like working at the forefront of the pharma industry? Working in one of our scientific roles provides you with the opportunity to be part of this work, having an impact on the lives of many. Come Learn. Come Grow with us. abzena.com/careers/vacanc…

In a recent article with Drug Target Review, we discuss one particular area of ADCs, whereby recent data questions what was traditionally thought on the therapeutic window of these drugs. Read the article here: drugtargetreview.com/article/110605…

As we're at the forefront of the ADC industry, it's only right we have up-to-date tech ThioBridge™ links antibodies/proteins to drugs. However it's not any old linker tech. It also maintains antibody stability and a consistent drug-to-antibody ratio abzena.com/capabilities/b…

1 day until the ADC Linker & Conjugation Summit, where we're lead partner! Be sure to come and say hello to see how our seamlessly integrated ADC offering provides you with a comprehensive pathway to success! Alternatively, contact us: abzena.com/contact/

Get to know our leadership team 🕵 Louise Duffy, PhD, Chief Technical Officer, has a wealth of expertise in the development of biopharmaceuticals, vaccines, cell & gene therapies and is an expert in antibody-drug conjugates! Find out more here: abzena.com/about/leadersh…

At Abzena, collaboration is key🤝 Working at Abzena, you’ll have the opportunity to contribute to the innovative development programs we do for clients and join forces with the brightest minds 🧠 If you would like to be part of this, check our vacancies: abzena.com/careers/vacanc…

Although antibody drug conjugates (ADCs) are a fairly new class of biopharmaceutical drugs, their mechanism of action as a targeted therapy for tumour cells is a well-established concept. But, how do they do this? Find out here: abzena.com/articles/adc-i…

In less than a weeks time, we'll be having a blast at the ADC Process Development Summit! The event will delve into the biggest issues drug developers face as they progress to and through clinical development. Be sure to catch us whilst you're there! See you there!

In our latest webinar released later this month, we discuss the importance of platform analytical strategies and consider the potential of applying this strategy to ADCs to help you expedite the path to IND! Be sure to follow us to not miss out when it's released!

In our latest webinar, we delve into how immunogenicity risk assessments have evolved over the years whilst presenting a case study that outlines how immunogenicity risk assessment can provide value for your vaccine development project. Find it here: abzena.com/articles/webin…

With quality a crucial foundation for everything we do, it is essential that our dedication to this is preserved. Currently, we have 2 openings in our quality team, both at our Bristol, PA site, so be sure to check them out if this interests you! abzena.com/careers/vacanc…